- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00645320
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
February 18, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone
The purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (Protocol A1281074).
Study Overview
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
RIO DE Janeiro RJ, Brazil, 22640-100
- Pfizer Investigational Site
-
-
Bahia
-
Salvador, Bahia, Brazil, 41180-000
- Pfizer Investigational Site
-
-
Ceara
-
Fortaleza, Ceara, Brazil, 60175-270
- Pfizer Investigational Site
-
-
MG
-
Belo Horizonte, MG, Brazil, 30150-270
- Pfizer Investigational Site
-
-
PR
-
Curitiba, PR, Brazil
- Pfizer Investigational Site
-
-
RJ
-
Rio de Janeiro, RJ, Brazil
- Pfizer Investigational Site
-
-
SP
-
Sao Paulo, SP, Brazil
- Pfizer Investigational Site
-
-
Salvador - BA
-
Jardim Santa Monica SN, Salvador - BA, Brazil, 40340-720
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Psychotic disorder
- Completion of previous study of intramuscular ziprasidone
- Ability to continue with oral ziprasidone
Exclusion Criteria:
- Concomitant treatment with other anti-psychotic agents within 12 hours prior to the enrollment; for depot agents, a period of two weeks or a cycle, whichever is longer, should occur between the last administration and the patient's enrollment.
- Treatment with antidepressants or mood stabilizers within seven days prior to the enrollment; for MAOIs (monoamine oxidase inhibitors) and moclobemide, this period should be of two weeks; for fluoxetine, five weeks.
- Resistance to conventional psychotic agents. (Resistance is defined as a failure to present a therapeutic response during the acute exacerbation after proper attempts of treatment with marketed antipsychotic agents in two or more occasions during the two years prior to the enrollment in the study.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months.
Doses were flexible based on investigator's discretion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Clinical Global Impression-Severity (CGI-S) score
Time Frame: Until Final Visit (within 3 months)
|
Until Final Visit (within 3 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: Baseline and Months 1, 2, and 3
|
Baseline and Months 1, 2, and 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Study Completion (Actual)
August 1, 2004
Study Registration Dates
First Submitted
March 21, 2008
First Submitted That Met QC Criteria
March 21, 2008
First Posted (Estimate)
March 27, 2008
Study Record Updates
Last Update Posted (Actual)
February 21, 2021
Last Update Submitted That Met QC Criteria
February 18, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A1281114
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pyschotic Disorders
-
Rennes University HospitalCompletedAtypical Cognitive DisordersFrance
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedOpioid Related DisordersUnited States
-
New York State Psychiatric InstituteSchering-PloughCompleted
-
Indivior Inc.CompletedOpioid-related DisordersUnited States
-
University Hospital, CaenUnknownAlcohol Disorders
-
Stanford UniversityCompletedPsychotic Disorders | Bipolar Disorder | Substance Use Disorders
-
Washington University School of MedicineRecruitingOpioid-Related DisordersUnited States
-
Biomedical Development CorporationNational Institute on Drug Abuse (NIDA); The University of Texas Health Science...Active, not recruitingOpioid-Related DisordersUnited States
-
Karlstad Central HospitalCompletedOpioid-Related DisordersSweden
Clinical Trials on Ziprasidone
-
Donald C. Goff, MDPfizerCompletedSchizophreniaUnited States
-
Bronx Psychiatric CenterPfizer; Buffalo Psychiatric Center; Rochester Psychiatric CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Pfizer; Ministry of Health, Spain; REM-TAP NetworkCompletedBorderline Personality DisorderSpain
-
Yale UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Dr. Reddy's Laboratories LimitedCompletedHealthyUnited States
-
Tufts Medical CenterPfizerCompletedDepression | Bipolar Disorder | Bipolar DepressionUnited States
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPsychotic Disorders | SchizophreniaTurkey, Egypt, Greece, Lebanon, Jordan, Kuwait, Saudi Arabia, South Africa, United Arab Emirates